Who Funds GMO Research? Conflicts of Interest, Independent Studies, and How to Judge the Evidence

When a public database of genetically modified organism (GMO) studies was released in the mid-2010s, critics and supporters immediately argued about who had paid for the research. Biotech supporters pointed to hundreds of studies finding GM crops safe; skeptics asked how many of those studies had financial ties to the companies that profit from the crops. The question matters because trust in science depends on confidence that results are not shaped by who funds them.

Research on research, sometimes called meta-research, now offers evidence on both sides of this question. Industry ties are common in GM crop research and are associated with more favorable conclusions in at least some areas. At the same time, independent, publicly funded studies, including large European Union projects designed to address public concerns, have generally reached the same conclusions about food safety. This article reviews what is known about funding and conflicts of interest in GMO research and how readers can evaluate the evidence.

Who funds GMO research, and can it be trusted? Much GMO safety research is funded or conducted by the companies that sell the products, which studies show makes favorable conclusions more likely. Independent, publicly funded studies like the EU’s GRACE and G-TwYST found no adverse effects of certain GM maize, supporting safety, but genuinely independent research remains scarce because funding and seed access are limited.

Why Do GMO Research Funding Sources Matter?

Who pays for research can shape its design, reporting, and conclusions, so knowing whether a GMO study was funded by industry or an independent source helps weigh how much confidence to place in it. Funding can influence research in subtle ways without any fraud. Sponsors choose which questions to study, which products to compare, and which outcomes to measure. They may influence study design, data analysis, interpretation, and whether results are published. Researchers with financial ties may unconsciously interpret ambiguous findings more favorably. Across many fields, studies show that industry sponsorship is associated with conclusions favorable to sponsors. A 2003 systematic review in JAMA by Justin Bekelman, Yan Li, and Cary Gross found that industry sponsorship of biomedical research was associated with pro-industry conclusions and that financial relationships among industry, scientists, and academic institutions were widespread. A 2017 Cochrane review by Andreas Lundh and colleagues confirmed that industry-sponsored drug and device studies more often had favorable efficacy results and conclusions than non-industry studies, a bias not explained by standard risk-of-bias assessments.

Nutrition research shows similar patterns. A 2007 study in PLOS Medicine by Lenard Lesser and colleagues found that nutrition articles on soft drinks, juice, and milk fully funded by industry were substantially more likely to reach conclusions favorable to sponsors than those with no industry funding. Our article on who funds agricultural research examines how industry money shapes university agricultural science more broadly.

Do Conflicts of Interest Affect GM Crop Studies?

Yes. One analysis found that studies with industry conflicts of interest were more likely to report outcomes favorable to the company, consistent with patterns seen in medicine and nutrition research. The most detailed analysis specific to GM crops comes from France. A 2016 study in PLOS ONE by Thomas Guillemaud, Eric Lombaert, and Denis Bourguet of the French National Institute for Agricultural Research examined 672 research articles on the efficacy or durability of insect-resistant Bt crops. They found that ties between researchers and the GM crop industry were common, with 40 percent of articles displaying conflicts of interest, either through industry funding or authors affiliated with companies. Compared with articles without conflicts, those with conflicts were associated with a 50 percent higher frequency of outcomes favorable to the interests of the GM crop company.

The authors proposed several mechanisms, including changes in authorship or funding statements after results were known and the selection of research topics driven by industry priorities. Importantly, this study examined whether Bt crops worked and how long they remained effective against pests, not whether GM foods were safe to eat. It shows that industry influence in this field is real and measurable, which supports calls for transparency and independent research, but it does not by itself show that food safety conclusions are wrong.

What Does the GMO Safety Research Actually Show?

Across hundreds of studies, including independent public ones, approved GM foods have not been shown to pose unique health hazards, and EU-funded studies found no adverse effects of specific GM maize in animal feeding trials. Studies on whether GM foods are safe to eat come from a mix of sources: companies seeking regulatory approval, academic researchers with and without industry ties, and government-funded programs. Reviews have generally concluded that approved GM foods are as safe as their conventional counterparts. A 2014 review by Alessandro Nicolia and colleagues examined about 1,800 scientific records and found no significant hazards directly connected to GE crops. A 2016 review in Food and Chemical Toxicology by José Domingo, who had earlier noted the scarcity of independent safety data, concluded that with few exceptions, studies from the previous six years found assessed GM soybeans, rice, maize, and wheat as safe as their parental species, though he called for more long-term studies on mutagenicity, teratogenicity, and carcinogenicity.

Studies reporting harm have received intense attention. A 2017 analysis in the Plant Biotechnology Journal by Miguel Sánchez and Wayne Parrott estimated that about 5 percent of GM safety studies reported adverse effects of concern, that these came from a small number of laboratories and lower-impact journals, and that close examination revealed methodological flaws. One author worked for an agricultural biotechnology industry association, a reminder that perspectives on all sides of this debate deserve the same scrutiny readers apply to studies reporting harm.

Independent Public Studies: GRACE and G-TwYST

To address public concerns and the controversy over a 2012 French study linking GM maize and Roundup to tumors in rats, the European Commission funded large independent research projects. The GRACE project (GMO Risk Assessment and Communication of Evidence) conducted feeding studies following European Food Safety Authority guidance and international test guidelines. A 2014 report in Archives of Toxicology by Dagmar Zeljenková and colleagues described two 90-day feeding trials of insect-resistant MON810 maize varieties in rats, which found no adverse effects at dietary levels up to 33 percent.

The follow-up G-TwYST project specifically tested the maize at the center of the 2012 controversy. A 2019 report in Archives of Toxicology by Pablo Steinberg and colleagues described two 90-day trials and a two-year feeding trial of glyphosate-tolerant NK603 maize, both untreated and treated with Roundup during cultivation, in male and female rats. The studies found no adverse effects on health, including no evidence of increased tumors. GRACE and G-TwYST also emphasized transparency, publishing protocols in advance and engaging stakeholders, including critics, in study design. These projects show that independent research can address contested questions directly.

Study or review	Funding	Main finding
Guillemaud et al. (2016)	French public research	40% of Bt efficacy studies had conflicts; more favorable outcomes
GRACE (2014)	European Commission	No adverse effects of MON810 maize in 90-day rat studies
G-TwYST (2019)	European Commission	No adverse effects of NK603 maize in 90-day and 2-year rat studies
Nicolia et al. (2014)	Academic review	No significant hazards directly linked to GE crops
Domingo (2016)	Academic review	Recent studies mostly find GM crops as safe as conventional; more long-term studies needed

Why Is Independent GMO Research So Scarce?

Independent research is limited because public funding is small, seed companies have historically controlled access to patented seeds for study, and researchers who publish critical findings can face pushback. Independent long-term research on GM crops has been limited for several reasons. Feeding studies are expensive, and public funding for food safety research is modest. Patent protections and licensing agreements historically restricted researchers’ access to GM seeds for independent study; in 2009, a group of university entomologists publicly complained to the Environmental Protection Agency that seed company agreements prevented them from conducting independent research, prompting some companies to loosen restrictions. Regulators typically rely on data submitted by developers seeking approval, which is standard across many industries but leaves the public dependent on company-generated studies unless independent work is funded. Strengthening independent funding and access would improve confidence regardless of what such research finds.

How Can I Evaluate a GMO Study Myself?

Check the funding and conflict-of-interest disclosures, look at sample size and study design, be wary of both industry and activist sources, and give most weight to findings replicated by independent researchers and reviewed by bodies without financial stakes. Readers can apply a few practical checks to any study on GM crops, whether it reports benefits or harms. Look at the funding statement and author affiliations, and check whether the authors declare competing interests. Consider the journal: established, peer-reviewed journals with strong editorial standards generally provide more reliable filtering, though no journal is perfect. Examine the study design: Were enough animals or participants included? Were appropriate controls used? Were statistical methods suitable, and were many outcomes tested without correction for chance findings? Check whether other independent groups have replicated the result. Finally, look at systematic reviews and reports from scientific bodies that weigh all available evidence rather than relying on a single study.

Beyond Food Safety: Where Funding Matters Most

Many of the most consequential questions about GM crops involve agronomy, economics, and the environment rather than food safety: how well traits work over time, how quickly pests and weeds evolve resistance, effects on pesticide use, and impacts on farmers’ incomes. The Guillemaud analysis suggests these are precisely the areas where industry ties are most common and potentially most influential, because companies have strong interests in demonstrating that their traits are effective and durable. Independent research on resistance management, herbicide use, and farm economics is therefore especially valuable for policymakers and farmers.

Transparency Reforms

Several reforms could strengthen trust in GM crop research. Journals can require detailed disclosure of funding and conflicts, including the role of funders in design, analysis, and publication. Researchers can preregister study protocols, as GRACE and G-TwYST did, so outcomes and analyses are specified before results are known. Regulators can make data submitted for approvals publicly available, a step the European Food Safety Authority took after its transparency regulation took effect in 2021. Seed companies can provide researchers unrestricted access to GM varieties for independent study. Governments can fund independent research on contested questions. These steps benefit everyone who wants evidence-based decisions.

The 2012 Rat Study Controversy

Few episodes illustrate the funding debate better than a 2012 study by French researcher Gilles-Éric Séralini and colleagues, which reported increased tumors and early deaths in rats fed glyphosate-tolerant NK603 maize and Roundup over two years. The study received worldwide media coverage, including dramatic photographs of rats with tumors. Critics, including regulatory agencies, argued that the study used a rat strain prone to spontaneous tumors, had too few animals per group to draw conclusions about cancer, and lacked appropriate statistical analysis. The journal retracted the paper in 2013, and it was republished in another journal in 2014. Supporters argued the retraction reflected industry pressure, noting that the journal had appointed an editor with former ties to the biotech industry. The European Commission funded G-TwYST partly in response, and its two-year study did not replicate the findings. The episode shows how disputes over funding and influence can affect both critics and defenders of GM crops.

Why Each Side Distrusts the Other

Critics of GM crops point to industry funding of research, the revolving door between companies and regulators, documented efforts by some companies to influence scientific publications, and the concentration of power in a few corporations. Supporters point to activist funding of some studies reporting harm, methodological problems in those studies, and the consistency of conclusions from scientific bodies worldwide. Both sides sometimes dismiss evidence based on its source rather than its quality. A more productive approach evaluates each study on its design and replication while supporting independent research and transparency to reduce the influence of any interest group.

The Role of Regulators

Regulatory agencies such as the U.S. Food and Drug Administration, the Environmental Protection Agency, the Department of Agriculture, and the European Food Safety Authority review data submitted by developers when deciding whether to approve GM crops. Critics argue that reliance on company data creates conflicts and that confidential business information limits public scrutiny. Regulators note that standardized test guidelines, good laboratory practice requirements, and independent review of submissions provide safeguards, and that requiring developers to fund testing is standard for pharmaceuticals and pesticides as well. Making regulatory data publicly accessible and funding independent verification studies, as the EU did, can address many concerns.

Questions to Ask About Any GMO Claim

Who funded the research, and what role did the funder play? Do the authors have relevant financial ties? Was the study published in a peer-reviewed journal, and has it been replicated? Does the claim come from a single study or a systematic review? Are the conclusions consistent with the data, or do they extend beyond what was measured? Is the claim about food safety, environmental effects, or economics? Applying the same questions to studies on both sides is the best defense against bias.

A Balanced View

Industry funding and conflicts of interest are common in GM crop research and are associated with favorable outcomes, at least in studies of how well GM traits work. That is a legitimate reason for scrutiny and for supporting independent research. At the same time, independent public studies on food safety, such as GRACE and G-TwYST, have reached conclusions consistent with industry and regulatory assessments. The evidence does not support dismissing all GMO safety research as industry propaganda, nor does it justify ignoring the influence of money on science. Transparency, independent funding, and careful evaluation of study quality serve the public interest.

Practical Takeaways

Check funding and conflicts of interest when reading about GMO research, but judge studies by their design and replication too. Give more weight to systematic reviews and independent public studies. Remember that food safety, environmental effects, and economics are different questions. Support policies that increase research transparency and independent funding. Choose organic or verified non-GMO foods if you prefer to avoid GM ingredients for any reason.

The Database Debate

Databases that catalog GM crop studies serve different purposes depending on who builds them. Some, compiled by researchers supportive of biotechnology, list hundreds of peer-reviewed studies and note how many had independent funding, arguing that a large share of the literature does not depend on industry money. Others, compiled by critics, highlight studies reporting adverse effects and question the independence of studies finding safety. Each type of database can be useful, but each also reflects choices about which studies to include and how to classify funding. Classifying funding is harder than it sounds: a university study may receive partial industry support, use industry-supplied materials, or involve authors with consulting ties not mentioned in the paper. Readers should look at the criteria behind any database and, where possible, at the underlying studies themselves.

How Funding Shapes the Questions

Perhaps the most important influence of funding is not on results but on which questions get asked. Industry funding naturally supports research on product performance, regulatory requirements, and commercial applications. Questions of less commercial interest, such as long-term ecological effects, comparisons with non-GM alternatives like agroecological pest management, or socioeconomic impacts on small farmers, may receive less attention unless public or philanthropic funders support them. As public funding for agricultural research has stagnated in some countries while private funding has grown, critics worry that research agendas increasingly reflect commercial priorities. Balanced research portfolios require sustained public investment.

What Scientific Organizations Recommend

Scientific organizations and journals have adopted policies to manage conflicts of interest, including mandatory disclosure, recusal of conflicted reviewers, and data-sharing requirements. The 2016 report on genetically engineered crops by the U.S. National Academies of Sciences, Engineering, and Medicine addressed public concerns about funding by describing its committee’s conflict-of-interest procedures and recommending more publicly funded research on GE crops and their alternatives. Many scientists across the spectrum of views on GMOs agree that independent research and transparency would improve public trust and decision-making.

Funding in Studies That Report Harm

Funding questions apply to critics as well. Some studies reporting adverse effects of GM foods have been funded by organizations opposed to GM crops or by companies selling organic or non-GMO products, and some authors have been affiliated with advocacy groups. Such ties do not automatically invalidate findings, just as industry funding does not, but they deserve the same disclosure and scrutiny. Readers who dismiss industry-funded studies while accepting advocacy-funded studies without question apply a double standard. The goal is consistent evaluation of methods, transparency, and replication regardless of the funder’s position.

Why Replication Matters Most

In science, the strongest protection against both bias and error is independent replication. A single study, no matter who funds it, can produce misleading results through chance, flawed design, or unconscious bias. When different research groups with different funding sources reach similar conclusions, confidence grows. On GM food safety, multiple independent groups and public projects have reached conclusions consistent with regulatory assessments. On questions such as the long-term durability of Bt traits and the effects of herbicide-tolerant systems, replication by independent researchers is still building and remains especially important.

Looking Ahead

As gene-edited crops enter the market, the same questions about funding and independence will arise. Many gene-edited crops are being developed by smaller companies and public institutions, which may change the research landscape. Regulatory systems are evolving, and calls for open data, preregistration, and independent verification continue to grow. Building trust in agricultural biotechnology, or deciding to reject it, will depend on whether the research behind it is transparent and independent enough to persuade a skeptical public.

What Consumers Can Do

Consumers who are skeptical of industry-funded research have options. They can choose USDA Organic or Non-GMO Project Verified foods, which avoid GM ingredients regardless of the scientific debate. They can support organizations and policies that promote independent agricultural research and open data. When reading news about GMO studies, they can look past headlines to check who conducted the research, how it was designed, and whether other studies agree. And they can recognize that concerns about corporate influence, herbicide use, and seed concentration are legitimate topics for public debate, separate from the question of whether approved GM foods are safe to eat. Engaging with these issues thoughtfully, rather than through slogans, helps move public debate toward better policy.

Lessons From Other Fields

The tobacco, sugar, and pharmaceutical industries offer historical examples of funders shaping research and public perception, from tobacco companies funding studies to cast doubt on smoking risks to the sugar industry funding research that shifted attention toward dietary fat in the 1960s. These cases explain why the public is wary of industry-funded science. They also led to reforms, including disclosure requirements and trial registration, that have improved transparency. Applying similar safeguards to agricultural research can help prevent comparable problems. The lesson from these histories is not that all industry-funded science is untrustworthy, but that disclosure, independent verification, and public access to data are essential whenever powerful financial interests are involved.

Common Myths

“All GMO safety studies are funded by Monsanto.” Many studies are publicly funded, including large EU projects.

“Industry funding means results are fake.” Funding is associated with favorable results but does not automatically invalidate a study.

“Independent studies always find harm.” Major independent feeding studies found no adverse effects.

“Studies reporting harm are always activist-funded junk.” Each study should be evaluated on its methods, not dismissed by source.

“Conflicts of interest only matter for safety.” They may matter most for questions of crop efficacy, resistance, and economics.

Key Terms

Conflict of interest: A financial or professional tie that could influence, or appear to influence, research.

Meta-research: Research that studies how research is conducted and reported.

Bt crop: A crop producing insecticidal proteins from the bacterium Bacillus thuringiensis.

Feeding trial: A study in which animals are fed a test food to assess health effects.

Preregistration: Publishing a study’s plan before collecting data to reduce selective reporting.

The Bottom Line

Questions about who funds GMO research are legitimate. A 2016 analysis found 40 percent of studies on Bt crop efficacy and durability had industry conflicts, which were associated with 50 percent more favorable outcomes, and industry funding is linked to favorable results across medicine and nutrition. At the same time, independent EU-funded studies, including a two-year rat feeding study of NK603 maize, found no adverse effects, consistent with major reviews of GM food safety. The evidence supports scrutiny of industry influence, stronger transparency, and more independent research, especially on agronomic, environmental, and economic questions, rather than either dismissing all GMO research or accepting it uncritically.

Frequently Asked Questions

Who funds most GMO research?

A large share of GMO research is funded or conducted by the agricultural companies that develop and sell genetically engineered seeds, because pesticide and seed approval systems require manufacturers to submit safety studies. Governments and universities fund some independent research, but public funding is comparatively small, so industry plays an outsized role in the evidence base.

Does industry funding bias GMO studies?

Research suggests it can. An analysis of GM crop studies found that those with financial or professional ties to industry were more likely to report conclusions favorable to the companies. This mirrors findings in medicine and nutrition and is why disclosure of funding and replication by independent researchers are so important for GMO science.

Is there any independent research showing GMOs are safe?

Yes. European Union-funded projects such as GRACE and G-TwYST, carried out by researchers without industry ties, found no adverse effects of specific GM maize in 90-day and long-term rat feeding trials. These and other independent studies, alongside industry research, support the conclusion that approved GM foods are as safe to eat as conventional ones.

Why is independent GMO research so limited?

Independent research is scarce because public funding for it is small, and seed companies have historically used patents and licensing agreements to control who can study their seeds and how. Researchers who publish findings critical of GMOs have also faced professional pushback, which can discourage independent investigation of controversial questions.

How can I tell if a GMO study is trustworthy?

Look at who funded the study and whether the authors disclose conflicts of interest, consider the sample size and quality of the design, and be cautious of both industry-sponsored and activist-driven research. The most reliable conclusions come from findings replicated by independent scientists and assessed by expert bodies without financial stakes in the outcome.

References

1. Guillemaud T, Lombaert E, Bourguet D. Conflicts of Interest in GM Bt Crop Efficacy and Durability Studies. PLOS ONE. 2016;11(12):e0167777. PMID 27977705
2. Bekelman JE, Li Y, Gross CP. Scope and impact of financial conflicts of interest in biomedical research: a systematic review. JAMA. 2003;289(4):454–465. PMID 12533125
3. Lundh A, Lexchin J, Mintzes B, et al. Industry sponsorship and research outcome. Cochrane Database of Systematic Reviews. 2017;2:MR000033. PMID 28207928
4. Lesser LI, Ebbeling CB, Goozner M, et al. Relationship between funding source and conclusion among nutrition-related scientific articles. PLOS Medicine. 2007;4(1):e5. PMID 17214504
5. Nicolia A, Manzo A, Veronesi F, Rosellini D. An overview of the last 10 years of genetically engineered crop safety research. Critical Reviews in Biotechnology. 2014;34(1):77–88. PMID 24041244
6. Domingo JL. Safety assessment of GM plants: An updated review of the scientific literature. Food and Chemical Toxicology. 2016;95:12–18. PMID 27317828
7. Sánchez MA, Parrott WA. Characterization of scientific studies usually cited as evidence of adverse effects of GM food/feed. Plant Biotechnology Journal. 2017;15(10):1227–1234. PMID 28710840
8. Zeljenková D, Ambrušová K, Bartušová M, et al. Ninety-day oral toxicity studies on two genetically modified maize MON810 varieties in Wistar Han RCC rats (EU 7th Framework Programme project GRACE). Archives of Toxicology. 2014;88(12):2289–2314. PMID 25270621
9. Steinberg P, van der Voet H, Goedhart PW, et al. Lack of adverse effects in subchronic and chronic toxicity/carcinogenicity studies on the glyphosate-resistant genetically modified maize NK603 in Wistar Han RCC rats. Archives of Toxicology. 2019;93(4):1095–1139. PMID 30756133

Last updated: October 6, 2026